Momenta Pharmaceuticals Initiates Phase 1 Trial of M281, an Anti-FcRn Monoclonal Antibody Biotech Investing
XBiotech Appoints Trey Benson as New Commercial Head to Lead Strategic Commercial Development for the Company’s Extensive Product Portfolio Biotech Investing
Oncothyreon Announces Corporate Name Change to Cascadian Therapeutics (NASDAQ: CASC) Biotech Investing
